GNH USA

Europe — EMA

Miglustat Accord

GNH USA supplies Miglustat Accord (Miglustat), an enzyme inhibitor for Gaucher disease type 1 and Niemann‑Pick disease type C. Request a quote worldwide.

Miglustat

Request sourcing

1
Pack/s

What is Miglustat?

Miglustat, the active ingredient in Miglustat Accord, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It is employed in the management of specific lysosomal storage disorders, notably Gaucher disease type 1 and Niemann‑Pick disease type C, by reducing the synthesis of glycosphingolipids that accumulate in patients.

GNH USA supplies Miglustat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across all markets.

What is Miglustat used for?

Miglustat acts on the glucosylceramide synthase pathway, addressing lysosomal storage disorders.

- Gaucher disease type 1: improves hematologic parameters and reduces spleen and liver volume. - Niemann‑Pick disease type C: slows neurological decline and stabilizes disease progression. - Lysosomal storage disease management: decreases accumulation of glycosphingolipids across affected tissues.

What are the side effects of Miglustat?

Miglustat may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Nausea - Abdominal pain - Weight loss

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions - Elevated liver enzymes

What precautions apply to Miglustat?

When prescribing Miglustat, clinicians should consider several safety measures.

- Liver function monitoring: assess hepatic enzymes before and during therapy. - Gastrointestinal tolerance: evaluate for persistent diarrhea or nausea. - Neurological assessment: watch for new onset tremor or depression. - Renal function: adjust use in patients with impaired clearance. - Hypersensitivity: discontinue if severe rash or anaphylaxis occurs. - Store at below 25°C: keep in original packaging, protect from moisture.

What does Miglustat interact with?

Miglustat can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce miglustat exposure. - Co‑administration with other glucosylceramide synthase inhibitors: risk of additive substrate reduction. - High-dose antacids containing magnesium or aluminum: can impair gastrointestinal absorption.

Moderate Interactions (Monitor Closely): - High‑fat meals: may increase gastrointestinal side effects. - Concomitant use of drugs that affect glucose metabolism: monitor blood sugar levels. - Certain antidepressants (e.g., SSRIs): observe for enhanced central nervous system effects.

Frequently asked questions

What is Miglustat Accord used for?+
Miglustat Accord is indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C, two rare lysosomal storage disorders. By reducing the synthesis of glycosphingolipids, the medication helps manage organ enlargement, blood abnormalities, and neurological symptoms associated with these conditions.
How does Miglustat work?+
Miglustat inhibits the enzyme glucosylceramide synthase, which catalyzes the first step in glycosphingolipid production. Blocking this pathway lowers the amount of substrate that accumulates in lysosomes, thereby decreasing cellular storage material and alleviating disease‑related pathology.
What is the usual dose of Miglustat Accord?+
The dosage of Miglustat Accord is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and renal function. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.
Is Miglustat safe during pregnancy or breastfeeding?+
Safety data for Miglustat in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.
How do I order Miglustat Accord from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity of Miglustat Accord. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.
How does Miglustat compare with the main alternative therapy?+
The primary alternative for Gaucher disease type 1 is enzyme‑replacement therapy (ERT), which supplies the missing enzyme. Miglustat offers a substrate‑reduction approach, decreasing the production of the offending lipid. While ERT directly replaces the deficient enzyme, Miglustat is oral and can be used when ERT is unavailable or as adjunct therapy, but it may have a different side‑effect profile.
How should Miglustat Accord be stored and handled?+
Miglustat Accord tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.
How is Miglustat Accord administered?+
Miglustat Accord is taken orally, typically with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Dosing times may be spaced to reduce gastrointestinal discomfort, as advised by the prescriber.
What are the most serious risks associated with Miglustat?+
Serious adverse events reported with Miglustat include pancreatitis, severe hypersensitivity reactions such as rash or angioedema, and significant elevations in liver enzymes. Patients should be monitored regularly for these conditions, and treatment should be stopped immediately if any serious reaction occurs.
Who should not use Miglustat Accord?+
Miglustat Accord is contraindicated in individuals with known hypersensitivity to miglustat or any of its excipients. It should also be avoided in patients with severe renal impairment unless dose adjustments are made under medical supervision. Clinicians must evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Miglustat
Route
Oral Use
Manufacturer
Accord Healthcare S.L.U.
Origin
EU

Related products

Miglustat 100 mg/1

Miglustat 100 mg/1

Miglustat · 100 mg

Miglustat
CAPSULE
CoTherix, Inc.
USA
Zavesca 100 mg

Zavesca 100 mg

Miglustat · 100 MG

Zavesca
CAPSULE
JANSSEN INC
CANADA
Sandoz Miglustat 100 mg

Sandoz Miglustat 100 mg

Miglustat · 100 MG

Sandoz Miglustat
CAPSULE
SANDOZ CANADA INCORPORATED
CANADA
Miglustat Accord

Miglustat Accord

Miglustat

Accord Healthcare Limited
EU